8-K: Schrödinger Reports Strong Q4 and Full-Year 2023 Results, Software Revenue Surges

Schrödinger announced a 44% increase in fourth-quarter software revenue and 20% total revenue growth for 2023, alongside a positive outlook for 2024.

Summary

• Schrödinger reported a strong fourth quarter and full-year 2023 financial performance, with total revenue for the fourth quarter increasing by 30.4% to $74.1 million compared to $56.8 million in the same period of 2022.
• Software revenue for the fourth quarter saw a significant increase of 43.6% to $68.7 million, up from $47.8 million in the fourth quarter of 2022.
• Full-year total revenue grew by 19.7% to $216.7 million, compared to $181.0 million in 2022, with software revenue increasing by 17.4% to $159.1 million.
• Drug discovery revenue decreased in the fourth quarter to $5.5 million from $9.0 million in 2022, but increased for the full year to $57.5 million from $45.4 million in 2022.
• The company's software gross margin improved to 87% in the fourth quarter and 81% for the full year.
• Schrödinger reported a net loss of $30.7 million for the fourth quarter but achieved a net income of $40.7 million for the full year, a significant turnaround from a net loss of $149.2 million in 2022.
• The company's total annual contract value (ACV) increased by 9.7% to $154.2 million, and the number of customers with an ACV of at least $1 million increased to 27 from 18.
• Schrödinger expects software revenue growth of 6% to 13% in 2024 and drug discovery revenue between $30 million and $35 million.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong revenue growth, improved profitability, and advancements in the drug discovery pipeline. The company's financial performance and future guidance are encouraging, suggesting a positive trajectory for the business.

Positives

• The company experienced strong growth in software revenue, with a 43.6% increase in the fourth quarter and a 17.4% increase for the full year.
• Schrödinger achieved a significant turnaround in profitability, reporting a net income of $40.7 million for the full year compared to a net loss of $149.2 million in the previous year.
• The software gross margin improved to 87% in the fourth quarter and 81% for the full year, indicating increased efficiency.
• The company's customer base is expanding, with a notable increase in the number of high-value customers with an ACV of at least $1 million.
• Schrödinger is making progress in its drug discovery pipeline, with multiple programs advancing to clinical trials and expected data readouts in the near future.
• The company has a strong cash position of approximately $468.8 million, providing financial stability for future growth.

Negatives

• Drug discovery revenue decreased in the fourth quarter, reflecting collaboration milestones that favorably impacted the fourth quarter of 2022.
• Operating expenses increased by 29.6% in the fourth quarter and 28.4% for the full year, primarily due to higher research and development expenses.
• The company reported a net loss of $30.7 million for the fourth quarter, despite a profitable full year.
• Cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023.

Risks

• The company's future performance is subject to the demand for its software platform and its ability to further develop its computational platform.
• Schrödinger relies on third-party providers of cloud-based infrastructure to host its software solutions, which could pose a risk.
• The company is exposed to fluctuations in the value of the U.S. dollar and foreign currencies.
• The drug discovery programs are subject to the uncertainties inherent in drug development and commercialization, including the timing of clinical trials and regulatory approvals.
• The company's ability to retain and hire key personnel is crucial for its success.

Future Outlook

Schrödinger expects software revenue growth of 6% to 13% in 2024, drug discovery revenue between $30 million and $35 million, and operating expense growth between 8% and 12%. They also anticipate initial data readouts from two clinical-stage programs in late 2024 or 2025 and plan to progress a third program to the clinic this year.

Management Comments

• Ramy Farid, Ph.D., chief executive officer of Schrödinger, stated that he is very pleased with the progress made in 2023, delivering 20 percent total revenue growth and reporting the largest quarter for software revenue in the company's history.
• Geoff Porges, MBBS, chief financial officer of Schrödinger, stated that the company had a very strong year in 2023, with significant growth in software and drug discovery revenue and substantial progress in the proprietary pipeline and at co-founded companies.

Industry Context

This announcement reflects the growing importance of computational platforms in drug discovery and materials science, with Schrödinger's strong software revenue growth indicating increasing adoption of its technology. The company's progress in its proprietary pipeline also highlights the trend of technology companies moving into drug development.

Comparison to Industry Standards

• Schrödinger's 43.6% increase in Q4 software revenue is significantly higher than the average growth rate for software companies in the life sciences sector, which typically ranges from 10-20%.
• The company's software gross margin of 87% in Q4 is also above the industry average, which is typically around 70-80% for software companies.
• Compared to companies like Certara and Simulations Plus, which also offer computational modeling software, Schrödinger's revenue growth is more robust, indicating a strong market position.
• The increase in customers with an ACV of at least $1 million from 18 to 27 demonstrates a strong ability to attract and retain high-value clients, which is a key metric for software companies.
• While companies like Relay Therapeutics and Recursion Pharmaceuticals are also advancing drug discovery programs, Schrödinger's approach of combining software and drug development is unique and positions them well for future growth.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and positive outlook.
• Employees may benefit from the company's growth and success.
• Customers will continue to benefit from the company's software platform and drug discovery capabilities.
• Suppliers and creditors will likely view the company as a stable and reliable partner.

Next Steps

• Schrödinger will continue to invest in the science underlying its platform.
• The company will focus on increasing customer adoption of its software.
• Schrödinger will advance its proprietary pipeline, including two clinical-stage programs.
• The company expects data readouts from its first two patient studies in late 2024 or 2025.
• Schrödinger is on track to progress a third program to the clinic this year.
• The company expects an IND submission for SGR-3515 in the first half of 2024 and start a Phase 1 trial in the second half of 2024.
• Schrödinger anticipates submitting at least one IND in 2025.

Key Dates

Keywords

Schrödinger, Software Revenue, Drug Discovery, Financial Results, Computational Platform, ACV, Clinical Trials, Pharmaceutical, Biotechnology